WHAT DRIVES US
At Diaceutics we believe that every patient should have access to the right treatment at the right time to positively impact their disease outcome, and we are committed to solving commercialization challenges.
We provide the world's leading pharma and biotech companies with an end-to-end commercialization solution for the launch of precision medicine through our platform.
DXRX - The Diagnostic Network®
Copyright © 2024, Diaceutics. All rights reserved
UNLOCK
MARKET CLARITY
Driving therapy re-adoption requires renewed market clarity, strategic insight and targeted activation
These real-world results show what’s possible with Diaceutics’ precision-driven approach
11×
more patients identified in FGFR3 rare disease vs traditional claims data
+19%
increase in action targets in CV disease programs
+35.6%
increase in new therapy starts in Precision Oncology
8%
market share growth in HemOnc by prioritizing diagnostic-triggered outreach
Up to 20:1
market share growth driven by smarter adoption
With Diaceutics, it’s not just about overcoming challenges. It’s about outperforming expectation.
UNCOVER HIDDEN BARRIERS BUILD A SMARTER STRATEGY
The 6A™ Landscape helps you uncover the hidden diagnostic, behavioral, and system barriers that are holding your therapy back turning fragmented signals into a strategic roadmap for renewed adoption and share growth.
Whether defending share in a competitive category or revitalizing a maturing brand, the Landscape equips you to:
The 6A™ Landscape gives you the clarity, structure, and expert-backed recommendations to act decisively ensuring your therapy reaches every patient it was designed to help.
REIGNITE THE KNOWLEDGE
When markets plateau, education isn’t the issue, belief is. Expert Exchange delivers peer to peer education that helps physicians reconnect with evolving science, refreshed evidence, and renewed conviction to act especially when therapy adoption has stalled:
ACCELERATE PRESCRIBING DECISIONS WHEN THERAPY ADOPTION FATIGUES
When therapy uptake slows, it’s often
due to a breakdown in engagement not awareness. Physician Engage enables you to overcome adoption fatigue and hesitation by delivering timely, credible education that reignites prescribing confidence in complex or competitive markets:
When every moment counts, speed matters. Physician Engage empowers you to reach the right prescribers with the right message fast so you can influence decisions before opportunities are lost..
RECLAIM LOST MOMENTUM WITH PRECISION TIMING
DXRX Signal reconnects brands with real time diagnostic and behavioural triggers, showing where eligible patients are being identified, which physicians are treating them, and when to re-engage:
See where patients are. Act when it counts. DXRX Signal gives you the precision to drive therapy adoption from day one.
Explore how our expert-led approach transforms insight into timely action - reigniting therapy adoption when it matters most.
We’re not just diagnosing the slowdown - we’re reversing it.
At Diaceutics, we help you reignite market momentum through data driven precision, combining real world diagnostic signals, behavioural insights and expert influence to reveal where opportunities have shifted , why uptake has slowed and how to reengage physicians with confidence.
See how real-time diagnostic data identifies eligible patients within 48 hours, enabling targeted, timely HCP engagement.
Bridge the gap between insight and action, so no eligible patient is left behind.
Reclaim lost momentum with precision timing
We partner with the world’s leading pharma and emerging biotech to accelerate therapy adoption, whether you are launching, scaling or reigniting momentum.
Supporting cross functional teams in commercial, marketing, medical, data, access and more, we deliver the precision insights and strategies needed to move faster and reach every eligible patient.
Across oncology, rare disease, neurology autoimmune and more, we help you unlock uptake with smarter strategy, real time physician action, and measurable impact.
Let’s reignite your strategy – together
Driving therapy re-adoption requires renewed market clarity, strategic insight and targeted activation
Navigating Precision Commercialization
Peter Finlayson, Rebecca Fryer & Sarah Kurz
11AM ET
18th November 2025
Partnering for Success in Rare & Precision Therapies
Upcoming Events
Ready to reignite therapy adoption?
Source: Data insights from Diaceutics’ client projects
maximize
PATIENT IMPACT
86%
HCP engagement rate through peer-led education
Reignite interest, drive clinical confidence, and re-establish relevance.